Authors:Tamás Csermely, Georg Petroianu, Kamil Kuca, Józsel Fűrész, Ferenc Darvas, Zsolt Gulyás, Rudolf Laufer, and Huba Kalász
Quaternary pyridinium aldoximes have been analyzed by thin-layer chromatography. Their separation was adequate when silica plates were used with a mobile phase with a high water content. As a consequence of their limited migration, reversed-phase TLC was not appropriate for determination of the lipophilicity of quaternary pyridinium aldoximes. Displacement TLC of some quaternary pyridinium aldoximes is, nevertheless, possible using silica as stationary phase with water-acetone-hydrochloric acid mobile phases. Normal-phase TLC with different concentrations of organic modifier gave a series of
values for the pyridinium aldoximes. Approximation of the different plots of
against organic modifier concentration to straight lines afforded
values and the slopes of the lines. The
values and the slopes both serve as indicators of the hydrophilic character of the compounds.
Authors:H. Kalász, R. Laufer, P. Szegi, K. Kuca, K. Musilek, and K. Tekes
The pharmacokinetics of K-203, a recently synthesized bis-pyridinium aldoxime, have been investigated by reversed-phase HPLC. The K-203 content of serum samples was monitored by HPLC with ultraviolet absorbance detection at 286 nm. The low concentration of K-203 in samples of brain, eyes, and cerebrospinal fluid was also determined by HPLC; quantitative evaluation was possible by use of an amperometric detector.
Authors:S.M. Nurulain, S. Ojha, S. Dhanasekaran, K. Kuča, N. Nalin, C. Sharma, A. Adem, and H. Kalász
Distribution of K027, a hydrophilic, positively charged compound is monitored in the body of pregnant mice using high-performance liquid chromatography (HPLC). Intraperitoneal injection was done on the 18th day of pregnancy; the plasma and brains of the mother mice, placentae and the fetuses’ brains were dissected following 5, 15, 30, 60, and 120 min of treatment. Significant incorporation of K027 was found in the placentae and in fetuses’ brains relative to its levels in the mothers’ plasma and brains. This incorporation warns of a possible adjustment of dose of pyridinium aldoxime antidotes in case of pregnancy. Further studies with different gestational periods and animal models are warranted.
Authors:Gellért Balázs Karvaly, Kornélia Tekes, Zoltán Szimrók, József FŰrÉsz, Kamil KuČa, and Huba Kalász
and without causing side effects. The antidote could be a single active agent, a precursor undergoing transformation and giving rise to the effective substance in the central nervous system, or a mixture of molecules. Quaternary mono- and bis-pyridinium